Conference Track

First-Line Therapy and Switch Strategies

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Capsule Summaries

Similar Clinical, Immunologic Outcomes for Antiretroviral-Naive HIV-Infected Patients Receiving PI-, NNRTI-, or PI Plus NNRTI–Based Therapy
Switching Patients With Suppressed Viral Load to Lopinavir/Ritonavir Monotherapy Durable and Well Tolerated to 48 Weeks in KalMo Study
Study 934: 96-Week Follow-up of Comparison of Tenofovir, Emtricitabine Plus Efavirenz vs Zidovudine/Lamivudine Plus Efavirenz in Treatment-Naive Patients
Differences in Updated CD4+ Cell Counts and Viral Loads May Explain Excess Risk of Death or Opportunistic Disease in SMART Study
Randomized Data Show Ritonavir-Boosted Fosamprenavir Noninferior to Lopinavir/Ritonavir in Treatment-Naive HIV Patients
Fixed-Cycle Structured Treatment Interruption Associated With Higher Risk of Disease Progression vs Continuous Therapy in HIV-Infected Africans
Switch to Lopinavir/Ritonavir Maintenance Monotherapy Associated With Similar Virologic Outcomes to Continued Treatment With Efavirenz Plus NRTIs
Lopinavir/Ritonavir Monotherapy Displays Similar Efficacy to HAART in Naive Patients, but Associated With More Low-Level Viremia: The MONARK Study
ACTG 5142: Initial Efavirenz-Based Therapy Associated With Superior Virologic Responses, Inferior Immunologic Responses Compared With Lopinavir/Ritonavir-Based Therapy
Switch From Lopinavir/Ritonavir to Atazanavir Has Similar Efficacy, Better Lipid Effects vs Continuation of Lopinavir/Ritonavir in Suppressed Patients
Switching to Lopinavir/Ritonavir Maintenance Monotherapy From Lopinavir/Ritonavir-Based HAART Noninferior to Continued HAART
SMART: Treatment Interruption Inferior to Continuous Therapy in Most Patient Subgroups

Expert Analysis

First-Line Therapy and Switch Strategies

Faculty:

David A. Cooper, MD, DSc
Joel E. Gallant, MD, MPH
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data comparing the outcomes of different first-line therapy regimens using FDA-approved agents
Describe data from a study of the integrase inhibitor MK-0518 in treatment-naive patients
Review the latest studies describing the outcomes of therapy with boosted-PI monotherapy in treatment-naive patients or those with virologic suppression on a standard HAART regimen
Recount findings from recent analyses of studies of treatment interruption strategies

CREDIT INFORMATION

Release Date: September 29, 2006

Expiration Date: September 28, 2007

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.